Role of Mutant TBP in Regulation of Myogenesis on Muscle Satellite Cells

Abstract

In polyglutamine (PolyQ) diseases, mutant proteins cause not only neurological problems but also peripheral tissue abnormalities. Among all systemic damages, skeletal muscle dystrophy is the severest. Previously by studying knock-in (KI) mouse models of spinal cerebellar ataxia 17 (SCA17), it was found that mutant TATA box binding protein (TBP) decreases its interaction with myogenic differentiation antigen, thus reducing the expression of skeletal muscle structural proteins and resulting in muscle degeneration. In this paper, the role of mutant TBP in myogenesis was investigated. Single myofibers were isolated from tibialis anterior muscles of wild type (WT) and SCA17KI mice. The 1TBP18 staining confirmed the expression of mutant TBP in muscle satellite cells in SCA17KI mice. In the BaCl₂-induced TA muscle injury, H&E cross-section staining showed no significant change in myofibril size before and after BaCl₂ treatment, and there was no significant difference in centralized nuclei between WT and SCA17KI mice, suggesting that mutant TBP had no significant effect on muscle regeneration. In the cultured primary myoblasts from WT and SCA17KI mice in vitro, representative BrdU immunostaining showed no significant difference in proliferation of muscle satellite cells. The primary myoblasts were then induced to differentiate and immunostained for eMyHC, and the staining showed there was no significant difference in differentiation of primary myoblasts between WT and SCA1KI mice. Our findings confirmed that mutant TBP had no significant effect on myogenesis.

Keywords

TATA box binding protein / spinocerebellar ataxia 17 / myoblast / myogenesis

References

[1] OrrHT, ZoghbiHY. Trinucleotide repeat disorders. Annu Rev Neurosci, 2007, 30: 575-621

[2] BatesGP, DorseyR, GusellaJF, et al.. Huntington disease. Nat Rev Dis Primers, 2015, 1: 15005

[3] PaulsonHL, ShakkottaiVG, ClarkHB, et al.. Polyglutamine spinocerebellar ataxias— from genes to potential treatments. Nat Rev Neurosci, 2017, 18(10): 613-626

[4] MartinB, GoldenE, KeselmanA, et al.. Therapeutic perspectives for the treatment of Huntington’s disease: treating the whole body. Histol Histopathol, 2008, 23(2): 237-250

[5] CarrollJB, BatesGP, SteffanJ, et al.. Treating the whole body in Huntington’s disease. Lancet Neurol, 2015, 14(11): 1135-1142

[6] CortesCJ, LingSC, GuoLT, et al.. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron, 2014, 82(2): 295-307

[7] LimJ, CrespoBJ, JafarNP, et al.. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature, 2008, 452(7188): 713-718

[8] AladãoPA, de AragãoBC, AndradeJN, et al.. Muscle atrophy is associated with cervical spinal motoneuron loss in BACHD mouse model for Huntington’s disease. Eur J Neurosci, 2017, 45(6): 785-796

[9] van Roon-MomWM, ReidSJ, FaullRL, et al.. TATA binding protein in neurodegenerative disease. Neuroscience, 2005, 133(4): 863-872

[10] VargasAP, Carod-ArtalFJ, BomfimD, et al.. Unusual early-onset Huntingtons disease. J Child Neurol, 2003, 18(6): 429-432

[11] HuangS, YangS, GuoJ, et al.. Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice. Cell Rep, 2015, 13(1): 196-208

[12] ForcinaL, MianoC, PelosiL. An Overview about the Biology of Skeletal Muscle Satellite Cells. Curr Genomics, 2019, 20(1): 24-37

[13] HuangS, LingJJ, YangS, et al.. Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. Brain, 2011, 134: 1943-1958 Pt7

[14] FriedmanMJ, ShahAG, FangZH, et al.. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci, 2007, 10(12): 1519-1528

[15] MitchellPO, MillsST, O’ConnorRS, et al.. Sca-1 negatively regulates proliferation and differentiation of muscle cells. Dev Biol, 2005, 283(1): 240-252

[16] HorsleyV, PavlathGK. Prostaglandin F2(alpha) stimulates growth of skeletal muscle cells via an NFATC2 dependent pathway. J Cell Biol, 2003, 161(1): 111-118

[17] ApponiLH, LeungSW, WilliamsKR, et al.. Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. Hum Mol Genet, 2010, 19(6): 1058-1065

[18] Kong D, He M, Yang L, et al. MR-17 and miR-19 cooperatively promote skeletal muscle cell differentiation. Cell Mol Life Sci, 2019, Jun. 18. [Epub ahead of print] doi:https://doi.org/10.1007/s00018-019-03165-7

[19] Huang S, Zhu S, Li XJ. The Expanding Clinical Universe of Polyglutamine Disease. Neuroscientist, 2019, Jan.7. [Epub ahead of print] doi:https://doi.org/10.1177/1073858418822993

[20] ZielonkaD, PiotrowskaI, MarcinkowskiJT. Skeletal muscle pathology in Huntington’s disease. Front Physiol, 2014, 5: 380

[21] GiorgettiE. Polyglutamine androgen receptor-mediated neuromuscular disease. Cell Mol Life Sci, 2016, 73(21): 3991-3999

[22] DupuisL. Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments. Curr Drug Targets, 2010, 11(10): 1250-1261

[23] RandoTA, BlauHM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol, 1994, 125(6): 1275-1287